What is Harm Reduction Coalition?
Harm Reduction Coalition operates as a national advocacy and capacity-building entity dedicated to promoting the health and dignity of individuals and communities impacted by drug use. The organization occupies a unique market position at the intersection of public health policy and social justice, working to dismantle the barriers that limit the voices of vulnerable populations. By championing harm reduction practices, the coalition addresses the multifaceted consequences of drug use, including HIV, hepatitis C, and the broader impacts of incarceration. Its operational model is built upon the principle that social inequality exacerbates health disparities, necessitating a comprehensive approach to policy reform and community empowerment.
How much funding has Harm Reduction Coalition raised?
Harm Reduction Coalition has raised a total of $1.1M across 2 funding rounds:
Unspecified
$750K
Debt
$350K
Unspecified (2019): $750K with participation from CVS Health
Debt (2020): $350K led by PPP
Key Investors in Harm Reduction Coalition
CVS Health
CVS Health is a diversified healthcare company providing healthcare services, pharmacy care, health benefits, and consumer health solutions. Its businesses include CVS Pharmacy, CVS Caremark, CVS Specialty, Aetna, and Oak Street Health, with a focus on improving access, affordability, and health outcomes.
PPP
Public-Private Partnership
What's next for Harm Reduction Coalition?
With the recent influx of capital, the Harm Reduction Coalition is positioned to accelerate its strategic objectives, focusing on the expansion of its national advocacy footprint and the enhancement of its programmatic infrastructure. The organization is expected to prioritize the scaling of its capacity-building efforts, ensuring that local communities are equipped with the resources necessary to implement effective harm reduction strategies. Furthermore, the coalition will likely deepen its engagement in the public policy dialogue, leveraging its increased financial stability to influence legislative frameworks that address the root causes of drug-related harm. This phase of development will be critical in solidifying the coalition's influence as a primary stakeholder in the national discourse on health equity and addiction services.
See full Harm Reduction Coalition company page
